Navigation Links
Baxa Addresses Health-System Capital Shortage With New Programs for IntelliFlowRx(TM) and IntelliFill i.v.(R)
Date:9/30/2009

dose management and IV room productivity. These products promote best practices for pharmacy operations, reduce drug waste, ensure dose accuracy and improve patient safety - one dose at a time.

Baxa Corporation, an exhibitor at the 44th American Society for Health-System Pharmacists (ASHP) Midyear Clinical Meeting in Las Vegas, will provide details of the IntelliSource program in their booth (101) at the Venetian Hotel and Sands Expo Center December 6th - 10th, 2009.

About Baxa Corporation

Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for medication handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of medications. Key products include the PadLock® Set Saver, Rapid-Fill(TM) Automated Syringe Fillers, ExactaMed® Oral Dispensers, MicroFuse® Syringe Infusers, Repeater(TM) Pharmacy Pumps, the IntelliFlow(TM) Rx System and ExactaMix(TM) Multi-Source Automated Compounders; used worldwide in hospitals and healthcare facilities. Its subsidiary FHT, Inc. produces the IntelliFilli.v.® automation. Privately held, Baxa Corporation has subsidiaries and sales offices in Florida, Canada and the United Kingdom; direct representation in Austria, Belgium, Denmark, Finland, France, Germany, Luxembourg, The Netherlands and Switzerland; and distribution partners worldwide. Further information is available at www.baxa.com.

    Contact:
    Marian Robinson, Vice President, Marketing
    Baxa Corporation:  800.567.2292 ext. 2157 or 303.617.2157
    Email:  marian.robinson@baxa.com

    Maggie Chamberlin Holben, APR
    Absolutely Public Relations: 303.984.9801 or 303.669.3558
    Email: '/>"/>
SOURCE Baxa Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. WBAL Radio Segment With Dr. Leigh Vinocur Addresses Hope for the Rosacea Sufferer
2. MannKind Addresses Pfizers Announcement Regarding Exubera
3. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
4. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
5. BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products, Now Available
6. Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments
7. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
8. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
9. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
10. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
11. Orthopaedic Surgeon Shortage Predicted Due to Soaring Joint Replacement Procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Drug safety remains front and center for the U.S. ... improve the public,s perception of the organization. Likewise, the ... consumers and recognizes that its diligence in the reporting ... effort. One issue that is impacting both ...
... 28, 2011 VirtualScopics, Inc. (Nasdaq: VSCP ), ... announced that before the market opens on Thursday, February 24, ... 2010 financial results. The company will host a conference call ... President and Chief Executive Officer, Jeff Markin, and Chief Business ...
Cached Medicine Technology:Navigating the Gray Areas of Post-Marketing Surveillance 2VirtualScopics Schedules Fourth Quarter/Full Year 2010 Earnings Announcement 2
(Date:4/18/2014)... University psychologists have made a brain-related discovery that ... disorders. , This discovery opens up the possibility ... suppress a specific brain activity that the researchers ... The Journal of Neuroscience has just ... McDonald, an associate professor of psychology and his ...
(Date:4/17/2014)... non-cancerous prostate tissue may have nearly twice the risk ... inflammation, according to results of a new study led ... , The link between persistent inflammation and cancer was ... those with a Gleason score between 7 and ... and rapidly growing prostate cancers. , "What we,ve shown ...
(Date:4/17/2014)... of Experimental Biology and Medicine a ... and Paul Kenis in the Institute of Genomic ... of Illinois Urbana-Champaign describe their recent work on ... variety of cell functions including energy metabolism, signaling, ... in regulating normal cellular behavior, redox status has ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... ... ... ... ...
... ... ... ... ...
... compared traditional surgery with less-invasive stenting to clear dangerously ... "seminal and robust." The Carotid Revascularization Endarterectomy vs. ... of both procedures are roughly equal. The trial, conducted ... the largest randomized stroke prevention trials ever. Loyola ...
... ... Conducts Statewide Outreach Efforts to Provide Low-Income Children Access to Dental Care ... ... Month draws to a close, California’s dental hygienists are reminding parents and ...
... 12,000 years ago, researchers say, , FRIDAY, Feb. 26 (HealthDay ... East more than 12,000 years ago, new research suggests. , ... IGF1 is a major determinant of small size in dogs. ... domestication of the Middle Eastern gray wolf, according to the ...
... evidence that newcomers hold mettle against warfarin, aspirin , ... more proof that the mainstays of anti-clotting therapy, namely ... newcomers. , Researchers presenting their findings during a ... meeting in San Antonio show that one new drug, ...
Cached Medicine News:Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 2Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 3Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 4Health News:American National Announces Corrected Dividend Dates 2Health News:Stents as good as surgery for clogged carotid arteries 2Health News:California Dental Hygienists Say National Children's Dental Health Month Should Be a Yearlong Effort 2Health News:California Dental Hygienists Say National Children's Dental Health Month Should Be a Yearlong Effort 3Health News:Current Blood Thinners Face Tough Competition 2Health News:Current Blood Thinners Face Tough Competition 3
... of infrared laser photocoagulators includes the OcuLight ... lasers serve as a single laser source ... no regular maintenance or special electrical/cooling, and ... The OcuLight SLx is now available with ...
The simplest, most accurate Ortho-K lens fitting system ever!...
... permeable contact lenses used for corneal refractive ... (myopia). The patient wears the lenses overnight ... During the day, nearsightedness is corrected or ... RG contact lenses apply slight pressure to ...
MDI will work with your facility to determine the best interim lab to fit your needs and your site....
Medicine Products: